#ESMO26 | 3530O UNION: Ph3 neoadjuvant SCRT followed by camrelizumab + chemo in locally advanced rectal cancer - 3y-EFS: 91.3% vs 77.4%, HR 0.33, p=0.0029 👉UNION is the first Ph3 to show EFS benefit with ICI in rectal cancer. Please note that the arms differed in both ICI use and radiotherapy (SCRT vs LCRT). @myESMO @OncoAlert